SCHEDULE 13G/A: Citadel Discloses 6.0% Stake in Acrivon Therapeutics
Beneficial Ownership Report
Citadel Advisors LLC and affiliated entities, including Kenneth Griffin, have disclosed a 6.0% beneficial ownership stake in Acrivon Therapeutics, Inc. as of March 31, 2025.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
- The filing reports beneficial ownership of common stock in Acrivon Therapeutics, Inc. (CUSIP: 004890109).
- As of March 31, 2025, Kenneth Griffin beneficially owns an aggregate of 1,895,618 shares, representing 6.0% of the outstanding common stock.
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each beneficially own 1,895,519 shares, also representing 6.0% of the outstanding common stock.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC each beneficially own 99 shares, representing 0.0% of the outstanding common stock.
- The percentages are based on 31,351,480 shares outstanding as of March 24, 2025, as reported in the issuer's Form 10-K filed on March 27, 2025.
- The Reporting Persons hold shared voting and dispositive power over their respective beneficially owned shares.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. The sentiment is neutral as it is a regulatory compliance filing.
Positives
- The disclosure of a significant 6.0% stake by a prominent investment firm like Citadel may signal increased institutional interest and confidence in Acrivon Therapeutics, Inc.
Industry Context
This filing indicates a significant investment by a major financial institution in a biotechnology company, which is a common occurrence in the sector as investors seek opportunities in emerging or established pharmaceutical and biotech firms. The passive nature of the investment, as indicated by the 13G filing, suggests a financial interest rather than an intent to influence corporate control.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Citadel may influence investor perception and potentially increase trading interest in Acrivon Therapeutics' stock.
Key Dates
| Date | Description |
|---|---|
| 2025-03-24 | Date as of which 31,351,480 shares of Acrivon Therapeutics, Inc. were outstanding, according to the issuer's Form 10-K. |
| 2025-03-27 | Date Acrivon Therapeutics, Inc. filed its Form 10-K with the SEC. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-05-15 | Date the Schedule 13G Amendment No. 3 was signed and filed. |
Keywords
Acrivon Therapeutics, Citadel Advisors, Kenneth Griffin, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.